Roth MKM Sticks to Their Buy Rating for HEALWELL AI (AIDX)
Roth MKM analyst Kyle Bauser reiterated a Buy rating on HEALWELL AI today and set a price target of C$2.50.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Bauser is an analyst with an average return of -13.0% and a 35.92% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Electromed, HEALWELL AI, and Apyx Medical.
In a report released on February 12, Haywood also maintained a Buy rating on the stock with a C$4.50 price target.
Based on HEALWELL AI’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of C$30.35 million and a GAAP net loss of C$27.86 million. In comparison, last year the company earned a revenue of C$13.74 million and had a GAAP net loss of C$10.57 million
Read More on TSE:AIDX:
Disclaimer & DisclosureReport an Issue
- HEALWELL AI Enters Middle East as Enterprise Healthcare Deployments Accelerate
- HEALWELL AI and WELL Health Unveil WELLTRUST Platform for Ethical AI-Driven Clinical Trial Recruitment
- HEALWELL AI: Strengthening Operating Engine, Orion Partnership, and Amadeus AI Launch Underpin Buy Rating and Long-Term SaaS Growth
- HEALWELL AI Advances Platform Integration and Expands Embedded Healthcare AI Offerings
- Healwell AI price target lowered to C$2 from C$2.50 at Scotiabank
